Skip to content
DataLookout
Menu

THRIVENCT06395506

THRIVE Well Cancer FDTN/Exercise_Creatine Supplementation

StatusActive, Not Recruiting
PhaseNot applicable
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 11 versions: 10 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 37 words Show 7 more changesShow less
    • Enrollment closed, study ongoing
    • Final enrollment: 39 participants (planned 60)
    • Primary completion date changed from estimate of May 31, 2028 to Oct 21, 2026
    • Study completion moved earlier from May 31, 2028 to Jul 31, 2027
    • Secondary endpoints: 3 to 2
    • Site details revised
    • Publications: details revised at 1 of 1 entry
  2. Minor Start date changed from estimate of Nov 1, 2024 to Oct 29, 2024v9
  3. Minor Start date: Oct 31, 2024 to Nov 1, 2024
    • Site contact updated
    v8
  4. Notable Start date: Sep 30, 2024 to Oct 31, 2024
    • Site contact updated
    v7
  5. Notable Start date: Aug 30, 2024 to Sep 30, 2024v6
Show 4 earlier versionsHide 4 earlier versions
  1. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date: Jul 30, 2024 to Aug 30, 2024
    • Site details revised
    v5
  2. Notable Start date: Jun 30, 2024 to Jul 30, 2024v4
  3. Notable Start date: May 31, 2024 to Jun 30, 2024v3
  4. Study Identification, Study Statusv2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Change in strength in breast cancer survivors
Timeframe: baseline and 12 weeks
Change in physical functional capacity in breast cancer survivors
Timeframe: baseline and 12 weeks

Secondary (2)

Change in body composition in cancer survivors
Change in the return of strength for breast cancer survivors with creatine + exercise

Arms and interventions

Age-Matched Control GroupNo intervention

Women who have never been diagnosed with cancer.

Creatine Supplement GroupExperimental

Those randomized to receive creatine (experimental group) will be initially dosed at 20 g/day for 7 days to boost availability of creatine systemically. Thereafter, the dose will be reduced to 5 g/day for maintenance through the duration of the 12-week protocol. Participants will engage in three center-based exercise sessions each week for 12 weeks; each session lasting roughly 1-hour. Participants will be given a fitbit (electronic watch that measures steps or heart rate) as well to track heart rate and monitor activity throughout the study.

Non-Creatine Supplement GroupNo intervention

Participants will engage in three center-based exercise sessions each week for 12 weeks; each session lasting roughly 1-hour. Participants will be given a Fitbit (electronic watch that measures steps or heart rate) as well to track heart rate and monitor activity throughout the study.

Dietary supplements: Creatine

Sites

1 site in 1 country

  • The University of Texas Medical Branch, GalvestonGalveston, Texas, United States